2025年4月3日 星期四
首页        期刊介绍        编委会        投稿指南        期刊订阅        广告合作        联系我们        English
河北医学  2021, Vol. 27 Issue (5): 873-877    DOI: 10.3969/j.issn.1006-6233.2021.05.037
  药物与临床 本期目录 | 过刊浏览 | 高级检索 |
托伐普坦联合奈西立肽治疗急性心力衰竭的疗效及对NT-proBNP cTnT sST2水平的影响
孙维1, 菅志飞1, 张继勇2
1.湖北医药学院附属东风医院/国药东风总医院急救医学部, 湖北 十堰 442000
2.武汉大学人民医院急救医学部, 湖北 武汉 430060
Efficacy of Tolvastan Combined with Nesiritide in the Treatment of Acute Heart Failure and Its Effect on The Levels of NT-proBNP cTnT and sST2
SUN Wei, JIAN Zhifei, et al
Dongfeng Hospital Affiliated to Hubei Medical College, Hubei Shiyan 442000, China
全文: PDF (1255 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的: 探讨托伐普坦联合奈西立肽治疗急性心力衰竭(AHF)的疗效及对N端脑利钠肽前体(NT-proBNP)、肌钙蛋白T(cTnT)、可溶性ST2(sST2)水平的影响。方法: 从我院收治的AHF患者中选取200例,按随机数字表余数法随机分为两组,对照组(n=100,予以奈西立肽)和观察组(n=100,予以托伐普坦+奈西立肽)。比较两组临床疗效、心室重构情况、血清NT-proBNP、cTnT、sST2表达水平及安全性。结果: 观察组治疗总有效率为93.00%,高于对照组的82.00%(P<0.05)。观察组治疗前后左室收缩期末期容积指数(LVESVI)、左室舒张期末期容积指数(LVEDVI)、左室质量指数(LVMI)的变化幅度明显高于对照组(P<0.05)。观察组治疗前后血清NT-proBNP、cTnT、sST2水平的变化幅度明显高于对照组(P<0.05)。两组不良反应发生率比较,观察组为6.00%,低于对照组的15.00%(P<0.05)。结论: 托伐普坦联合奈西立肽治疗AHF的效果优于单纯的奈西立肽,不仅能延缓心室重构,还能减少血清NT-proBNP、cTnT、sST2的表达,降低不良反应发生率。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
孙维
菅志飞
张继勇
关键词 急性心力衰竭托伐普坦奈西立肽N端脑利钠肽前体肌钙蛋白T可溶性ST2    
AbstractObjective: To investigate the efficacy of topaplatin combined with nesiritide in the treatment of acute heart failure (AHF) and its effect on the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), troponin T (cTnT) and soluble ST2 (sST2). Methods: 200 patients with AHF were randomly divided into the control group (n = 100, nesiritide) and the observation group (n = 100, tovapritide + nesiritide) according to the method of residues of random number table. The clinical efficacy, ventricular remodeling, serum NT-proBNP, cTnT, sST2 expression and safety were compared between the two groups. Results: The total effective rate of the observation group was 93.00%, which was higher than that of the control group (82.00%) (P<0.05). The changes of left ventricular end-systolic volume index (LVESVI), left ventricular end-diastolic volume index (LVEDVI) and left ventricular mass index (LVMI) in the observation group were significantly higher than those in the control group before and after treatment. The changes of serum NT-proBNP, cTnT and sST2 levels in the observation group before and after treatment were significantly higher than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 6.00%, which was lower than that in the control group (15.00%) (P<0.05). Conclusion: Tovaptan combined with nesiritide is superior to nesiritide in the treatment of AHF. It can not only delay ventricular remodeling, but also reduce the expression of serum NT-proBNP, cTnT and sST2 and reduce the incidence of adverse reactions.
Key wordsAcute heart failure    Tovaptan    Nesiritide    N-terminal pro-brain natriuretic peptide    Troponin T    Soluble ST2
    
基金资助:湖北省自然科学基金,(编号:2018CFB275)
通讯作者: 菅志飞   
引用本文:   
孙维, 菅志飞, 张继勇. 托伐普坦联合奈西立肽治疗急性心力衰竭的疗效及对NT-proBNP cTnT sST2水平的影响[J]. 河北医学, 2021, 27(5): 873-877.
SUN Wei, JIAN Zhifei, et al. Efficacy of Tolvastan Combined with Nesiritide in the Treatment of Acute Heart Failure and Its Effect on The Levels of NT-proBNP cTnT and sST2. HeBei Med, 2021, 27(5): 873-877.
链接本文:  
http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.05.037     或     http://www.hbyxzzs.cn/CN/Y2021/V27/I5/873
冀ICP备2025106803号    冀公网安备13080202000786号
版权所有 © 2016 《河北医学》杂志社
本系统由北京玛格泰克科技发展有限公司设计开发